08 nov: Cargotec's Kalmar provides XVELA collaborative stowage solution t..
08 nov: P.A.M. Transportation Services, Inc. Announces Preliminary Result..
08-11-2017 15:01:38

Zealand Pharma: Interim report for the first nine months of 2017

Relateret indhold
17 nov - 
Aktier/åbning: Genmab tager føringen efter bonus i posi..
17 nov - 
Aktier/tendens: Genmab og ISS kan komme i fokus i afdæm..
16 nov - 
Torsdagens aktier: Genmab og GN forrest i bedste dag si..
Relateret debat
20:28 - 
Det er vist dig som snart skal have en rescuepen udi då..
20:27 - 
Det er en uafhængig 3. part som anslå r recepttall ene ..
20:26 - 
Det er en uafhængig 3. part som anslå recepttallen ud f..

Company announcement - No. 50/2017

Interim report for the first nine months of 2017

Copenhagen, November 8, 2017 - Zealand Pharma A/S ("ZEAL") announces financial results and continued strong progress for its product candidates and business for the first nine months of 2017. Financial guidance for 2017 has been revised with 4-6% lower operating expenses.

Financial results for the first nine months of 2017

  • Revenue of DKK 128.5 million/USD 20.4 million[1] (DKK 54.3 million/USD 8.1 million2 in the first nine months of 2016).
  • Net operating expenses3 of DKK 251.7 million/USD 39.9 million1 (DKK 220.9 million/USD 33.1 million2 in the first nine months of 2016).
  • Net result of DKK -162.3 million/USD -25.7 million1 (DKK -206.7 million/USD -31.0 million2 in the first nine months of 2016).
  • Cash position of DKK 780.6 million/USD 123.8 million1 per September 30, 2017 (December 31, 2016: DKK 642.1 million/USD 91.0 million4, including restricted cash).

Business highlights for Q3 2017

  • Listing on the Nasdaq Global Select Market in the U.S. raising gross DKK 567 million/USD 90 million[1].
  • Initiation of Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.
  • Orphan drug designation for dasiglucagon for the treatment of congenital hyperinsulinism was granted by FDA in the U.S.
  • Boehringer Ingelheim initiated Phase 1 trial in the amylin analog program, triggering a EUR 4 million milestone payment to Zealand.
  • Boehringer Ingelheim initiated Phase 1 trial in the GLP-1/glucagon dual agonist program.
  • Soliqua® 100/33 revenue increased 37% and payer coverage increased 4%-point over the previous quarter to cover 65% of commercial lives.

Business highlights for the period thereafter

  • Orphan drug designation for glepaglutide for the treatment of short bowel syndrome granted by FDA in the U.S.
  • The potential for less than once-daily dosing with glepaglutide is being evaluated in a clinical trial, following positive results in the Phase 2 trial for Short Bowel Syndrome.
  • Patient enrolment completed for Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.

Britt Meelby Jensen, President and CEO of Zealand

, comments:

"We continue to see strong results and progress with our clinical product candidates, and following the U.S. IPO in August, where we raised USD 90 million, we are in a solid position to advance our late stage clinical programs at full speed. For glepaglutide, we are in preparation to start Phase 3 mid-2018, we received orphan drug designation and we are finalizing a trial to assess the potential for a better dosing option for patients. In addition, two of our partnered programs have advanced to Phase 1 for treatment of obesity and/or diabetes. With this, I am convinced that Zealand is set for a successful future."

Revised financial guidance for 2017 

For 2017, Zealand maintains its revenue guidance of a continued increase in royalty payments from Sanofi. No specific guidance on the level of royalties can be provided as Sanofi has not provided any guidance on expected 2017 sales.

Milestone revenue of DKK 101 million has been received from partners.

Net operating expenses in 2017 are expected to be within the range of DKK 375-385 million, 4-6 % lower than previously guided (DKK 390-410 million). The decrease relates to timing of clinical studies as well as tight cost control.

Operating loss before royalty income/expenses has been reduced from DKK 290-310 million to DKK 275-285 million.

Conference call today at 4 pm CET/10 am EST

Zealand's management will be hosting a conference call today at 4 pm CET/10 am EST to present the results for the first nine months of 2017. Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session.

The dial-in numbers are:

DK standard access             +45 32711658

UK and international            +44 (0) 20 3427 1907

U.S. (free dial-in)                 +1 646 254 3366

Passcode                            3321181

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/m6/p/wr84wf2d also accessible on the Investor section of Zealand's website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website after the call.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

[1] Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.30 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2017.

2 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.68 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2016.

3 Net operating expenses consist of research, development and administrative expenses less other operating income.

4 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 7.05 per USD 1.00, which was the rounded official exchange rate of such currencies at December 31, 2016.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/c335bc3e-baed-4c37-a6b9-4a9afa57572a

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
17 nov
ZEAL
Zealand Pharma (ny analyse) Langt sigt: Stærkt køb   Zealand Pharma - analyse 14-11-2017   Kurs på a..
6
10:17
ZEAL
Det australiske lægemiddelmyndighed TGA har den 27. oktober 2017 godkendt Soliqua på følgende indika..
5
17 nov
ZEAL
»Kortsigtet er det selvfølgelig altid skuffende med en sådan kursreaktion, men det er et resultat af..
5
10:54
ZEAL
Den 27. oktober har Lægemiddelstyrelsen offentliggjort at det er blevet besluttet at Suliqua per 1. ..
4
17 nov
ZEAL
Det ved du 'selvsagt' også beskedent om, som alt andet 'desangående' og ihvorvel som dit øvrige 'løs..
4
12 nov
ZEAL
Jeg syntes at det ser ud som om 2/3 af lægerne kan se en eller anden point med dette produkt, hvilke..
4
09:20
ZEAL
Jeg gentager: Få dig et liv ud over al den spam du trollagtigt sidder og fyrer af her i døgndrift!
3
17 nov
ZEAL
Pattebarnet GW har lige fået nye smileys som skal vises frem i hvert indlæg han skriver nu
3
16 nov
ZEAL
k1 du er virkelig noget af det laveste EI fremviser. Et ekko af alt det Danmark ikke skal være, men ..
3
13 nov
ZEAL
Executive Vice President og Chief Financial Officer i Zealand Pharma Mats Blom har købt 15000 aktier..
3

Rockwool køber resten af mindre schweizisk selskab

17-11-2017 15:05:59
Rockwool har overtaget ejerskabet af den schweiziske isoleringsproducent Flumroc.Rockwool og Flumroc har haft en samarbejdsaftale siden 1969, og dengang købte det danske selskab en mindre aktiepost, som siden er øget til 43,5 pct.Fredag har det danske selskab købt de resterende aktier i selskabet, oplyser Rockwool i en pressemeddelelse.Flumroc har 230 ansatte og en årlig omsætning på omkring 67 mi..

Vestas: Britisk selskab investerer flere millioner på kursfald

17-11-2017 14:33:34
Det britiske investeringsselskab Marshall Wace har øget sit sats på kursfald i Vestas-aktien til en shortposition på 1,22 pct., hvilket i kroner og ører svarer 1,1 mia. kr.Tidligere lå positionen på 1,14 pct., viser indberetninger til Finanstilsynet.Vestas kom i sidste uge med et regnskab for tredje kvartal, som var præget af en intensivering af konkurrencen, hvilket har skabt usikkerhed om indtje..

Aktier/middag: Vestas og Mærsk trækker C20 Cap i rødt

17-11-2017 11:33:13
Stemningen er overvejende negativ på det danske aktiemarked fredag formiddag, hvor langt størstedelen af eliteaktierne i C20 Cap-indekset er på retur. Særligt Vestas og Mærsk-aktierne er presset i bund.Dermed kommer markedet igen ned på jorden efter to dage i streg med stigninger - og en endog ret stor en af slagsen torsdag.C20 Cap-indekset falder med 0,6 pct. til 1121,62, og ser man på hele ugen ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 92,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. november 2017 20:43:55
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171108.1 - EUROWEB2 - 2017-11-18 20:43:55 - 2017-11-18 20:43:55 - 1 - Website: OKAY